Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine long-term safety in Japanese pediatric depression
NCT03395353Phase 3Terminated
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of duloxetine in major depressive disorder (MDD), persistent depressive disorder (PDD), sponsored by Shionogi & Co., Ltd.. Started Jan 2018; status: terminated.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on NCT03395353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395353.